Latest news with #JonnaKim
Globe and Mail
3 days ago
- Business
- Globe and Mail
TD Cowen Keeps Their Buy Rating on Gap Inc (GAP)
In a report released today, Jonna Kim from TD Cowen maintained a Buy rating on Gap Inc (GAP – Research Report). The company's shares closed today at $22.33. Confident Investing Starts Here: Kim covers the Consumer Cyclical sector, focusing on stocks such as American Eagle, Gap Inc, and Bath & Body Works. According to TipRanks, Kim has an average return of 21.7% and a 44.12% success rate on recommended stocks. The word on The Street in general, suggests a Moderate Buy analyst consensus rating for Gap Inc with a $28.33 average price target, implying a 26.90% upside from current levels. In a report released today, Morgan Stanley also maintained a Buy rating on the stock with a $27.00 price target. See Insiders' Hot Stocks on TipRanks >> Based on Gap Inc's latest earnings release for the quarter ending February 1, the company reported a quarterly revenue of $4.15 billion and a net profit of $206 million. In comparison, last year the company earned a revenue of $4.3 billion and had a net profit of $185 million Based on the recent corporate insider activity of 80 insiders, corporate insider sentiment is negative on the stock. This means that over the past quarter there has been an increase of insiders selling their shares of GAP in relation to earlier this year. Most recently, in March 2025, Elisabeth B Donohue, a Director at GAP sold 3,539.00 shares for a total of $74,460.56.
CNBC
29-04-2025
- Business
- CNBC
TD Cowen lowers view on this telehealth stock
Telehealth company Hims & Hers has limited near-term upside potential, according to TD Cowen. The firm downgraded shares to hold from buy in a Tuesday note. Analyst Jonna Kim also lowered her price target to $30 per share from $44, which indicates shares gaining just 5.3% from Monday's close. The "stock could be range-bound in a post GLP-1 shortage world," Kim said in the research note. "Near-term upside may be limited, but we like the story for the long-term as HIMS remains committed to making healthcare accessible for all." GLP-1 medications treat diabetes and obesity and had been in shortage due to heavy demand. Although the analyst expects strong first-quarter results due to compounded demand for weight loss drugs, she believes the remainder of the year looks difficult. Hims & Hers will not be selling compounded versions of Wegovy and Ozempic after May 22, following the Food and Drug Administration's announcement that the GLP-1 shortage is over. Unless current GLP-1 users opt to switch to other oral medication options such as Liraglutide — in addition to the likelihood of users looking elsewhere for GLP-1 options — Him & Hers' current 2025 weight loss revenue guidance appears overly optimistic, according to Kim. In addition, "recession risk and muted consumer demand could be factors to monitor," Kim said. Year to date, shares of the telehealth company have advanced nearly 18%. The stock has soared about 127% over the last 12 months. —CNBC's Michael Bloom contributed to this report.
